Viridian Therapeutics to Present at Three Upcoming Investor Conferences
February 22, 2021 08:00 ET
|
Viridian Therapeutics, Inc.
BOULDER, Colo., Feb. 22, 2021 (GLOBE NEWSWIRE) -- Viridian Therapeutics, Inc. (NASDAQ: VRDN), a development-stage biopharmaceutical company, today announced that Jonathan Violin, Ph.D., President...
miRagen Therapeutics Announces Company Name Change to Viridian Therapeutics and New Executive Appointments, Including Expansion of Leadership Team
January 19, 2021 07:00 ET
|
Viridian Therapeutics, Inc.
Jonathan Violin, Ph.D., M.B.A. appointed President, CEO and director Barrett Katz, M.D., M.B.A. joins Viridian as Chief Medical OfficerViridian is developing VRDN-001 and VRDN-002 for the treatment of...
miRagen Enters into License Agreement with Xencor for use of Xtend™ Antibody Technology for Investigational Antibodies to Treat Thyroid Eye Disease
December 17, 2020 07:00 ET
|
miRagen Therapeutics, Inc.
Company obtains exclusive rights to develop and commercialize antibody therapeutics targeting insulin-like growth factor-1 receptor (IGF-1R) using Xencor’s Xtend™ half-life extension technology ...
miRagen Reports Third Quarter 2020 Financial Results and Provides Corporate Updates
November 10, 2020 16:15 ET
|
miRagen Therapeutics, Inc.
Recently completed acquisition of Viridian Therapeutics, including an anti-IGF-1R monoclonal antibody, VRDN-001, for the potential treatment of thyroid eye disease (TED)Private placement financing...
miRagen Therapeutics, Inc. Announces Acquisition of Viridian Therapeutics, Inc.
October 28, 2020 07:00 ET
|
miRagen Therapeutics, Inc.
Acquisition includes clinical stage anti-IGF-1R monoclonal antibody, VRDN-001, intended for the treatment of thyroid eye disease (TED) Company plans to use private placement financing proceeds of...
miRagen Announces Internal Review of Preliminary Topline Data for the Phase 2 SOLAR Clinical Trial of Cobomarsen in Patients with Cutaneous T-Cell Lymphoma (CTCL)
October 05, 2020 16:05 ET
|
miRagen Therapeutics, Inc.
BOULDER, Colo., Oct. 05, 2020 (GLOBE NEWSWIRE) -- miRagen Therapeutics, Inc. (NASDAQ: MGEN), a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted...
miRagen Announces Leadership Transition and Review of Strategic Alternatives
September 14, 2020 17:00 ET
|
miRagen Therapeutics, Inc.
Lee Rauch appointed President and CEO, following resignation by William Marshall miRagen will undertake an in-depth review of its portfolio Ladenburg Thalmann engaged as financial advisor BOULDER,...
miRagen Announces Results of Meeting With FDA Regarding the Design of Pivotal Trial for Cobomarsen in ATLL
August 20, 2020 16:05 ET
|
miRagen Therapeutics, Inc.
BOULDER, Colo., Aug. 20, 2020 (GLOBE NEWSWIRE) -- miRagen Therapeutics, Inc. (NASDAQ: MGEN), a clinical-stage biopharmaceutical company focused on the discovery and development of proprietary...
miRagen Reports Second Quarter 2020 Financial Results and Provides Business Updates
August 05, 2020 16:05 ET
|
miRagen Therapeutics, Inc.
Progress on next generation microRNA-29 mimic for use in pulmonary fibrosis (MRG-229) includes new preclinical data; additional NIH grant funding triggeredExploratory preclinical safety and...
miRagen to Present at the 2020 Wedbush PacGrow Healthcare Virtual Conference
August 04, 2020 08:00 ET
|
miRagen Therapeutics, Inc.
BOULDER, Colo., Aug. 04, 2020 (GLOBE NEWSWIRE) -- miRagen Therapeutics, Inc. (NASDAQ: MGEN), a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted...